RESEARCH TRIANGLE PARK, N.C. — Icagen
(Nasdaq: ICGN), which reported a setback in the trial of its lead drug candidate earlier this week, said Thursday its losses increased in the second quarter.
Icagen shares fell 4 cents to close at 99 cents.
Icagen loss $6.3 million. Revenues were $2.6 million.
The company's stock has been pummeled this week since it announced a data monitoring committee had recommended that patients not receiving additional treatment in con junction with its sickle cell drug ICA-17043 be withdrawn from the trial.



![[READ STORY]](http://wwwcache.wral.com/asset/news/national_world/national/2013/05/14/12445890/12446751-1368816960-100x75.jpg)
![[VIEW PAGE]](http://wwwcache.wral.com/asset/news/local/2013/05/13/12441232/hahn-100x75.jpg)
![[GALLERY]](http://wwwcache.wral.com/asset/entertainment/2013/03/28/12278304/LNL-100x75.jpg)
![[VIEW PAGE]](http://wwwcache.wral.com/asset/traffic/2009/07/23/5645694/beltline-100x75.jpg)
![[GALLERY]](http://wwwcache.wral.com/asset/entertainment/2013/03/04/12182235/12182236-1362457268-100x75.jpg)

WRAL.com welcomes your comments on this story. All comments are moderated prior to publication based on our posting guidelines. Please review them prior to posting and if your message is not approved.
This story is closed for comments.